SCI Abstract

search
+
Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews
Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews
Trigeminal neuralgia (TN) and postherpetic neuralgia (PHN) are severe peripheral neuropathic pain conditions associated wi...
The Long Road to Long-Acting: What Oral PrEP and CAB-LA Teach Us About Scaling Lenacapavir
The Long Road to Long-Acting: What Oral PrEP and CAB-LA Teach Us About Scaling Lenacapavir
Despite significant biomedical advances, human immunodeficiency virus (HIV) remains a persistent global health crisis, wit...
Ecnoglutide: First Approvals
Ecnoglutide: First Approvals
Ecnoglutide is a cyclic adenosine monophosphate (cAMP)-biased glucagon-like peptide-1 (GLP-1) receptor agonist being devel...
Comparative Efficacy of Non-opioid Analgesic Drugs for Chronic Cancer Pain: A Bayesian Network Meta-analysis
Comparative Efficacy of Non-opioid Analgesic Drugs for Chronic Cancer Pain: A Bayesian Network Meta-analysis
While opioids remain the primary pharmacological intervention for cancer pain management, their clinical utility is freque...
Balancing Act: The Dual Roles of BAFF in Systemic Lupus Erythematosus
Balancing Act: The Dual Roles of BAFF in Systemic Lupus Erythematosus
In systemic lupus erythematosus (SLE) and other autoimmune diseases, B-cell activating factor (BAFF) and a proliferation-i...
Orforglipron: First Approval
Orforglipron: First Approval
Orforglipron (Foundayo™) is an orally administered, non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist bei...
Emerging Strategies Targeting the PI3K/AKT/mTOR Pathway in HR+/HER2– Advanced Breast Cancer
Emerging Strategies Targeting the PI3K/AKT/mTOR Pathway in HR+/HER2– Advanced Breast Cancer
Hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer...
DLL3-Targeted Strategies in Advanced Prostate Cancer: Current Evidence and Future Perspectives
DLL3-Targeted Strategies in Advanced Prostate Cancer: Current Evidence and Future Perspectives
Inhibition of androgen receptor (AR) signaling remains the cornerstone of systemic therapy for advanced prostate cancer (P...
Acoziborole: First Approval
Acoziborole: First Approval
Acoziborole (Acoziborole Winthrop), a single-dose, oral antiprotozoal agent, has been developed by Drugs for Neglected Dis...
Lunsotogene Parvec: First Approval
Lunsotogene Parvec: First Approval
Lunsotogene parvec (lunsotogene parvec-cwha; OTARMENI™) is a dual adeno-associated virus (AAV) gene transfer therapy...
Small-Cell Lung Cancer: Biology, Translational Science and Clinical Innovation
Small-Cell Lung Cancer: Biology, Translational Science and Clinical Innovation
Small-cell lung cancer (SCLC) is widely considered one of the most aggressive human malignancies, characterized by develop...
Andamertinib: First Approval
Andamertinib: First Approval
Andamertinib (安比锐®) is a tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EG...
Cefepime/Zidebactam: First Approval
Cefepime/Zidebactam: First Approval
Cefepime/zidebactam (Zaynich®), a fixed-dose combination of the fourth-generation cephalosporin cefepime and the ^...
Non-invasive Assessment and Therapeutic Targeting in Metabolic Dysfunction-Associated Steatohepatitis (MASH): Overcoming the Dissonance Between Drug Development and Precision Medicine
Non-invasive Assessment and Therapeutic Targeting in Metabolic Dysfunction-Associated Steatohepatitis (MASH): Overcoming the Dissonance Between Drug Development and Precision Medicine
Despite two decades of therapeutic clinical trials in metabolic dysfunction-associated steatotic liver disease (MASLD), on...
Baxdrostat: First Approval
Baxdrostat: First Approval
Baxdrostat (BAXFENDY™) is a first-in-class, highly selective and potent aldosterone synthase inhibitor being develop...
Vepdegestrant: First Approval
Vepdegestrant: First Approval
Vepdegestrant (VEPPANU; formerly ARV 471) is a novel PROteolysis TArgeting Chimera (PROTAC) that is able to simultaneously...
Plasma Biomarker Effects of Oral Valiltramiprosate/ALZ-801 in Early Alzheimer’s Disease from Phase 3 and Phase 2 Trials: Analysis of Core Biomarkers and Correlations with Clinical and Neuroimaging Outcomes
Plasma Biomarker Effects of Oral Valiltramiprosate/ALZ-801 in Early Alzheimer’s Disease from Phase 3 and Phase 2 Trials: Analysis of Core Biomarkers and Correlations with Clinical and Neuroimaging Outcomes
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder with few treatment options, especially for APOE...
Gepirone Extended-Release: First Approval
Gepirone Extended-Release: First Approval
Gepirone HCL extended-release (gepirone ER; EXXUA™), an oral, selective serotonin (5HT)1A receptor agonist formulate...
New Therapies on the Horizon for Primary Biliary Cholangitis
New Therapies on the Horizon for Primary Biliary Cholangitis
Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease that can progress to cirrhosis and hepatic failur...
Zilucoplan: First Approval
Zilucoplan: First Approval
Zilucoplan (Zilbrysq®) is a subcutaneously administered macrocyclic peptide inhibitor of complement component 5 (C5 i...
Vamorolone: First Approval
Vamorolone: First Approval
Vamorolone (AGAMREE®) is an oral, selective, dissociative corticosteroid developed by ReveraGen BioPharma and Santher...
Pharmacological Treatments of Temporomandibular Disorders: A Systematic Review Including a Network Meta-Analysis
Pharmacological Treatments of Temporomandibular Disorders: A Systematic Review Including a Network Meta-Analysis
Temporomandibular disorders (TMD) comprise a cluster of conditions with a wide range of etiological factors that causes pa...
Reply to the Comments on “Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study”
Reply to the Comments on “Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study”
Funding The original article was supported by funding from Chung Sh...
Comment on: “Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study”
Comment on: “Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study”
Conflict of interest TWC and C-HH declare that they have no competi...
Targeting KRAS-Mutated Gastrointestinal Malignancies with Small-Molecule Inhibitors: A New Generation of Breakthrough Therapies
Targeting KRAS-Mutated Gastrointestinal Malignancies with Small-Molecule Inhibitors: A New Generation of Breakthrough Therapies
Kirsten rat sarcoma virus (KRAS) is one of the most important and frequently mutated oncogenes in cancer and the mutationa...
Narlumosbart: First Approval
Narlumosbart: First Approval
Narlumosbart (津立生) is a recombinant, fully human, anti-receptor activator of nuclear factor kappa- ...
Spesolimab for the Treatment of Generalized Pustular Psoriasis
Spesolimab for the Treatment of Generalized Pustular Psoriasis
Generalized pustular psoriasis (GPP) is a rare but severe skin inflammatory disorder characterized by the eruption of wide...
Poly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges
Poly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges
The use of glucagon-like peptide-1 (GLP-1) receptor-based multi-agonists in the treatment of type 2 diabetes and obesity h...
Correction to: Motixafortide: First Approval
Correction to: Motixafortide: First Approval
In the published PDF version, Section 2.1 Pharmacodynamics, second paragraph, sixth s...
Efficacy and Safety of the Travoprost Intraocular Implant in Reducing Topical IOP-Lowering Medication Burden in Patients with Open-Angle Glaucoma or Ocular Hypertension
Efficacy and Safety of the Travoprost Intraocular Implant in Reducing Topical IOP-Lowering Medication Burden in Patients with Open-Angle Glaucoma or Ocular Hypertension
A randomized, double-masked, multicenter, phase 2 trial to evaluate the long-term safety and efficacy of travoprost intrao...
Load More
format_indent_increase